Investor Presentaiton
6
IDEAYA Precision Medicine Oncology Platform
Fully-Integrated Target, Biomarker, Drug Discovery and Translational Capabilities
Target & Biomarker
Discovery and Validation
.
•
.
Bioinformatics, including Al Algorithms
Dual CRISPR, CRISPR, Chemogenomics
Genetically Engineered Models
Drug Discovery and
Pharmacological Validation
Key emerging novel targets identified, such as
Werner Helicase, Pol Theta Helicase and PARG
DECIPHER™ - Dual CRISPR SL Library in DDR
Cell Lines in collaboration with UCSD
PAGEOTM - Paralogous Gene Evaluation in
Ovarian in collaboration with Broad Institute
Machine Learning and Multi-Omics platform
Structure Based Drug Design
Small Molecule Chemistry
Protein Degrader Capabilities
Translational Research and
Opportunity Expansion
Genomics - DNA and RNA Analysis
Proteomics - Protein Expression Profiling
Tissue (IHC, IF) and Liquid Biopsies Analysis
Crystal structures for SL discovery programs
obtained to enable structure-based design
INQUIRE™ Chemical Library - proprietary,
expert-curated small-molecule library
• HARMONY™ Machine-Learning engine
empowers drug discovery platform
Differentiated clinical / candidate compounds
discovered, including IDE397, IDE161 and
GSK101/IDE705 (Pol Theta Helicase)
•
.
.
Translational research to define
clinical biomarkers
Opportunity expansion through
broad cell panel screening
Pharmacodynamic biomarker
analysis to confirm target
modulation and correlation
with clinical activity
IDEAVA
BIOSCIENCESView entire presentation